A pilot study finds longer delays (more than 4 years) were associated with history of uveitis, ankylosing spondylitis at diagnosis, and being in the most vulnerable socioeconomic group.
Black box warnings for JAK inhibitors arise from rheumatoid arthritis studies, leading one expert to question the risk-benefit relevance to dermatologic diseases, particularly in younger patients.